H Clinical Gets Majority Backing for Latin American Trials

A sponsor can choose Latin America for its patient populations and still lose weeks to the handoffs between sites, nurses, recruiters, couriers, equipment suppliers and country rules. Clinical research becomes local long before a global protocol reaches a patient's home.

That operating problem is what H Clinical and its new majority owner are putting capital behind. Emerald Square Ventures has made a majority investment in the clinical-research services company, pairing new ownership with an unusually direct management transition.

What H Clinical and Emerald Square Announced

The companies announced the transaction on September 16, 2026. Financial terms, valuation and the exact ownership percentage were not disclosed, but the majority designation makes this more than a passive growth check: Emerald Square is taking control while H Clinical continues under President and CEO Mitchell Parrish.

Emerald Square's co-founders are also moving into operating roles. Ben Joers becomes CFO, responsible for financial strategy, planning and infrastructure, while Eddie Hannush becomes CCO, leading commercial strategy, client relationships and service growth. Parrish remains CEO, giving the company a leadership structure that combines continuity with two investors now accountable for daily execution.

What H Clinical Actually Operates

H Clinical supports pharmaceutical sponsors, contract research organizations and research sites through its own in-country teams across 22 Latin American countries. The company connects four service layers that are often purchased and managed separately: clinical-research staffing; community-based patient recruitment; in-home and hybrid trial visits; and procurement and logistics.

Those services turn a regional strategy into physical work. H Clinical recruits and manages coordinators, nurses and other study personnel; works through physicians, health centers, patient associations and community events; supports sample collection and shipments from patients' homes; and maintains depots, sourcing, equipment-rental and courier capacity. The company is headquartered in St. Petersburg, Florida, with regional headquarters in Mexico City and São José dos Campos, Brazil.

Why the Operating Handoffs Matter

Decentralized trials are sometimes discussed as if moving an appointment away from a research site makes the process lighter. The FDA's guidance on decentralized elements says otherwise: in-home visits and local provider activity still require clear protocols, qualified personnel, training and consistent data collection. Convenience for the participant creates a different execution burden for the sponsor.

Latin America adds country-level regulatory, language, cultural and logistics differences to that burden. Brazil alone now operates under Law 14,874/2024 and ANVISA's RDC 945/2024, while every other market has its own institutions and operating reality. A regional vendor can create value when it owns enough of those handoffs to keep a study from becoming a relay race between disconnected providers.

That is H Clinical's commercial thesis. The company says a sponsor or CRO can use one operating platform for staffing, recruitment, home visits, equipment and logistics instead of rebuilding those relationships country by country. The announcement does not provide audited cost savings, enrollment gains, retention improvements or timeline reductions, so the integrated model should be understood as an operating proposition rather than a proven outcome.

Why Emerald Square Is Becoming the Operator

Emerald Square Ventures describes itself as a hybrid of private equity and entrepreneurship focused on clinical research and life sciences. Joers brings an investment-banking and private-equity background to finance and M&A; Hannush brings enterprise sales, partnerships and go-to-market experience. Their decision to take executive jobs makes the investment thesis visible inside H Clinical's organization.

This matters because H Clinical's assets are not confined to software or a central facility. Its value depends on people who understand local sites and communities, plus the depots, equipment, courier networks and regulatory work that let those people carry out a protocol. A majority owner can fund expansion, but Joers and Hannush also inherit responsibility for growing that system without stripping away the local relationships Parrish says took years to build.

What the Investment Will Fund

H Clinical says the investment will expand the services clients are requesting and the in-country teams behind them. That includes site and project staffing, community-based patient recruitment, in-home and hybrid trial support, procurement, local sourcing, regional depots, equipment rental and courier networks.

The announcement leaves the budget and timetable open. It does not identify new countries, hiring targets, planned acquisitions, named customers or financial milestones. The clearest disclosed change is organizational: H Clinical now has a majority owner whose founders are responsible for the financial and commercial machinery needed to turn demand into regional capacity.

The Broader Clinical-Trial Infrastructure Bet

The World Health Organization's clinical-trial guidance identifies limited participant diversity, insufficient infrastructure and weak integration with local health systems as global research problems. H Clinical operates in the space between that policy objective and the practical question sponsors face: who hires the people, reaches the communities, moves the equipment and completes the visit under each country's rules?

Emerald Square is betting that the answer can become a larger regional business if ownership, finance and commercial execution sit closer to the field operation. Parrish keeps the CEO role, Joers takes the financial controls and Hannush takes the client-growth mandate. The next stage will be built in the handoffs they can make reliable across 22 countries, one study, site, shipment and patient visit at a time.